

From: Chief Officer

Sent: 25 March 2026 10:19

To: Chief Officer <chiefofficer@leics-lpc.co.uk>

Cc: ServiceDevelopmentLead <ServiceDevelopmentLead@leics-lpc.co.uk>

Subject: Early Information on upcoming LLR ICB Medicines Formulary alignment work programs

Importance: High

FAO: ALL LLR Pharmacy Teams

Please find below important communications from LLR ICB regarding upcoming formulary changes, which will come into effect over the next few months.

Action: Please read this information carefully and disseminate within your pharmacy teams. You may also wish to review your current stock of the affected items.

From: Medicines Optimisation Team Leicester, Leicestershire, and Rutland (LLR) ICB

We would like to advise you of a medicine Formulary alignment work programme which we anticipate will be implemented across GP practices in Leicester, Leicestershire, and Rutland (LLR) ICB within the next 3 months.

We are sharing this information at this early stage as a courtesy to support community pharmacy contractors in planning ahead, particularly in relation to stock management and to help ensure continuity of care for patients who may be affected by the upcoming changes. This forms part of our due diligence and our commitment to working collaboratively with community pharmacy.

The proposed changes will be aligned with the LLR Formulary and LLR APC guidelines, and are expected to include the following:

- **Anticoagulation: Generic apixaban and generic rivaroxaban will become the first-choice anticoagulants for patients with non-valvular atrial fibrillation (NVAf) where clinically appropriate.**
- **Edoxaban will no longer be considered first line for this indication.**

We appreciate your co-operation and understanding. Providing this early indication aims to help community pharmacy prepare appropriately and to support ensure a smooth transition for patients when the final changes are implemented.

Kind Regards
Rajshri Owen MRPharmS
Chief Officer